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Simian-human immunodeficiency virus (SHIV) infection in the macaque is a model of HIV pathogenesis. KB9, a molecular
clone of SHIV 89.6P, induced rapid and profound CD4 T cell loss in rhesus monkeys, followed by partial recovery in some.
We describe another clinical outcome after intravenous SHIV-KB9 inoculation in two of six infected rhesus macaques: lack
of signs of immunodeficiency with sustained CD4 T cell counts, despite virus load levels similar to those of the animals with
CD4 lymphocyte decline. To dissect the role of host factors in determining pathogenicity of this viral clone, humoral and
cellular immune responses were studied. Differences in CD8 T cell effector responses and activation profiles and in thymic
output, but not in specific antibody production, were observed in animals with different disease outcomes during acuteINTRODUCTION
Simian immunodeficiency virus (SIV) infection of ma-
caques is a useful model of pathogenesis of lentivirus
infection. However, a major limitation of the macaque
model is that SIV is antigenically distinct from human
immunodeficiency virus (HIV) types 1 and 2 and is not an
appropriate challenge virus for human vaccine and anti-
viral compound studies. The construction of SHIV chime-
ras, where the env, tat, and rev genes of SIV were
replaced by those of HIV-1, was a breakthrough in this
direction. One such virus, SHIV-KB9, originally observed
to cause a uniquely rapid and profound CD4 cell loss
and AIDS-like immunodeficiency disease, was described
(Karlsson et al., 1997; Reimann et al., 1996). Such rapid
lymphodepletion may be due to thymic disruption in-
duced by the virus (Ilda et al., 2000). However, in subse-
quent studies, this virus was found to display variability
in disease progression patterns (Reimann et al., 1999).
Infection resulted in rapid and profound CD4 T cell loss
in 5 of 15 animals infected, without antibody production
against viral antigens, and a substantial but less pro-
found and partially reversible CD4 T cell depletion with
rapid seroconversion in the other two-thirds. The level of
plasma viremia did not differ between SHIV-KB9-infected
1 To whom correspondence and reprint requests should be ad-47animals exhibiting these different outcomes (Reimann et
al., 1999). We describe herein yet another outcome of
SHIV-KB9 infection in two of six rhesus macaques: A
pattern of nonprogressive infection, characterized by
persistence of normal CD4 cell counts and rapid anti-
body seroconversion, without any clinical or laboratory
evidence of immunodeficiency, despite virus load mea-
surements comparable with those of the animals which
did exhibit CD4 lymphodepletion. In this study, we fur-
ther characterize cellular and humoral immunologic re-
sponses and thymic output in the animals exhibiting the
contrasting patterns of disease.
RESULTS
Clinical and immunological course after SHIV-KB9
infection
Consistent with previous reports, we noted variability
in the clinical outcomes of monkeys infected with SHIV-
KB9. However, we further noticed that a group of animals
did not show any clinical or laboratory sign of immuno-
deficiency, despite comparable levels of plasma viremia.
Two of the six animals (group A, RBJ-5, RAQ-5) displayed
a pattern of rapid and profound CD4 lymphocyte deple-
tion, reaching a nadir of 50 CD4 cells/cu mm within 2
weeks postinfection without recovery (Fig. 1) and died 2
and 8 months after infection, respectively, due to diar-infection. Thymic involvement may thus be a critical factor
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14 weeks after inoculation. In both of these instances a
modest CD4 T cell increase was observed. At autopsy
they both exhibited severe thymic involution. Two other
animals (group B, RHR-5, RQI-5) exhibited a pattern of
rapid but less pronounced CD4 lymphocyte loss to a
nadir of approximately 150 CD4 cells/cu mm, but par-
tially recovered their CD4 lymphocytes (Fig. 1) and have
remained alive 20 months postinfection. In one of these
(RQI-5), treatment with PMPA was started at 8 weeks
after inoculation, after which a CD4 increase was ob-
served; however, the medication was discontinued 4
weeks later with sustained increase in the CD4 T cell
count after its discontinuation. The two remaining ani-
mals (group C, RDO-5, RAP-5) did not show any signs or
symptoms of disease and their CD4 counts remained at
preinfection levels (Fig. 1).
The CD8 lymphocytes displayed a transient decrease
followed by a more sustained increase in groups A and
B and were preserved until late disease. The two ani-
mals of group C showed only transient modest CD8 T
cell count increases that soon stabilized to preinfection
levels. Several activation markers on the CD8 lympho-
cytes were studied. There was an increase in the pro-
portion of activated CD8 lymphocytes following infec-
tion, as demonstrated by expression of HLA-DR and
CD69 markers (Fig. 2). The animals in which the CD4
counts were not affected (group C) showed the smallest
increases of CD8 lymphocyte activation marker expres-
sion. Much greater increases were observed in the an-
imals that demonstrated CD4 depletion; those with par-
tial CD4 T cell recovery (group B) had the most pro-
nounced activation levels of CD8 lymphocytes (Fig. 2).
By 14 weeks after inoculation, HLA-DR expression on
CD8 cells had waned to preactivation levels in all
groups. At the acute infection stage there was an in-
crease in the percentage and absolute count of CD8
lymphocytes not expressing the CD45 RA marker in the
animals that demonstrated CD4 T cell declines and
disease progression, but not in those that did not (Fig. 2).
We further observed that there was a loss of CD4
“naı¨ve” CD45RA cells, concomitantly or slightly follow-
ing the total CD4 T lymphocyte decline. In contrast, the
percentage of CD8 CD45RA naı¨ve cells was preserved
and even increased, both during acute and chronic in-
fection.
Plasma viral RNA levels in the SHIV-infected monkeys
Specimens for virus load quantitation were collected
at different time points postinoculation. As seen in Fig. 3,
the highest levels of virus replication during primary
infection were seen in all animals at 2–4 weeks postin-
oculation. By 10 weeks, virus replication had decreased
dramatically and persisted at levels near the limit of
detection for several months. Only one animal (RAQ-5,
from Group A) had a high virus load at 14 weeks post-
inoculation; virus load became undetectable 8 weeks
later, after initiation of PMPA therapy. With regards to the
effects of PMPA on virus load, our data do not allow us to
conclude with certainty what the extent of the effect was.
The animals placed on PMPA were all started on the
medication after the primary infection phase (6 weeks
postinoculation), so its effects on viral and immune pa-
rameters in the acute phase of infection cannot be eval-
uated. In the case of RBJ-5, therapy was started at 6
weeks after inoculation, when the virus load had already
declined to the limit of detection; in RAQ-5, PMPA was
started at 14 weeks after inoculation, and the virus load
did decrease from 8.54 log to undetectable within 8
weeks. Finally, in RQI-5, treatment was started at 8
weeks postinoculation, when the virus load was 4.8 log,
and discontinued 4 weeks later, with virus load levels
that had become and subsequently remained undetect-
able. So PMPA seemed to help in curtailing viral replica-
tion, but the extent of its contribution to the overall viral
and immune kinetics of the infection is unclear.
Plasma viral RNA levels during either primary or
chronic infection did not differ among the groups with
different disease progression patterns.
Evolution of envelope-specific antibody responses in
rhesus monkeys infected with SHIV-KB9
We characterized the evolution of virus-specific anti-
body responses to the HIV-1 envelope, by analyzing
longitudinally serum samples from the KB9-infected rhe-
sus monkeys with the different disease patterns. As
shown in Fig. 4, quantitative and qualitative changes in
HIV-1 envelope-specific serum antibody were apparent
during the first several months postinoculation in all
three groups. Serum antibodies directed against HIV-
1gp120 were detectable in all animals by 1 month post-
FIG. 1. CD4 T lymphocyte counts in rhesus macaques infected with
SHIV-KB9 demonstrating different clinical outcomes: Monkeys that did
not demonstrate any CD4 T lymphocyte count decreases after inoc-
ulation (RDO-5, RAP-5), monkeys whose CD4 T lymphocyte nadir after
inoculation was 50 cells/L and partially recovered their CD4 T
lymphocyte numbers (RHR-5, RQI-5), and monkeys whose CD4 T
lymphocyte nadir after inoculation was 50 cells/L and which failed
to substantially recover their CD4 T lymphocyte numbers (RBJ-5,
RAQ-5).
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inoculation. Levels increased subsequently, reaching
maximum titers by 2–3 months. The two monkeys of
group A only showed a transient and weak response
(Fig. 4A): one of them (RBJ-5) died at 10 weeks postin-
oculation; the other (RAQ-5) demonstrated a modest in-
crease in antibody titer up to three times the background
levels but lost the antibody by 10 weeks postinoculation
and did not develop a response afterward. In the other
four animals, once maximum titers were achieved, they
were maintained at relatively constant levels for at least
6 months postinfection for both progressors and nonpro-
gressors (Fig. 4A). After 6 weeks postinoculation, the two
animals from group B reached two- to fourfold higher
antibody titers than the two nonprogressors of group C
(Fig. 4A).
Qualitative changes in antibody avidity were also ob-
served during this time (Fig. 4B). While low avidity index
values of about 8–15% were evident at 2 months postin-
FIG. 2. CD8 T lymphocyte activation marker expression after SHIV-KB9 infection. The percentage of CD8 T cells positive for HLA-DR, CD69, or
negative for CD45RA, in animals of the different groups are shown in (A), (B), and (C), respectively. Group A: RBJ-5, RAQ-5; Group B: RHR-5, RQI-5;
Group C: RDO-5, RAP-5.
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fection, these gradually increased during the first 10
months, reaching maximum values of 35–45% for both
progressors and nonprogressors.
These data demonstrate a gradual maturation of HIV-1
envelope-specific serum antibodies in response to SHIV
infection during the first several months postinoculation,
characterized by increasing antibody titer and avidity. It
appears that virus-specific antibody requires about 8–10
months to fully mature and is independent of clinical
course, as evidenced by the similar patterns of antibody
maturation in the animals that progressed compared
with those that remained asymptomatic.
In contrast, antibodies to tetanus became detectable
in most cases after the first dose and reached high titers
after the second dose of the vaccine in all but one animal
from group A. Antibody avidity to tetanus toxoid reached
very high levels (80–90%) in all animals by 1–2 months
after the first dose of the vaccine (data not shown).
Cytokine production in response to viral antigens
ELISPOT assays were performed with PBMC stimu-
lated with recombinant antigens, including four SIVmac
Gag peptide pools, SIVmac Nef, and HIVMN gp120. In
general, the six monkeys displayed broad reactivity to
the different viral antigens (Fig. 5). Of note was the fact
that the highest frequency of IFN--producing cells was
observed in response to Gag antigens, followed by Nef;
the lowest reactivity was observed toward gp120, similar
to previous observations (Kuroda et al., 1998; Larsson et
al., 1999). The added frequencies of T cells specific to the
different antigens were up to 872 per 105 PBMC in the
monkeys from group A, 2265 in the monkeys from group
B, and 1010 in the animals from group C at 2 weeks
postinoculation; the respective frequencies at 6 weeks
were 420, 1115, and 827, respectively. The range of fre-
quencies of SFC to all six antigens in our animal cohort
per 105 PBMC was Gag, 0–446; Nef, 0–539; and
HIVgp120, 0–824. Thus, the animals with resistance to
disease displayed similar responses compared to those
with disease; in fact, the highest responses were ob-
served in those animals which exhibited partial CD4 T
cell recovery after an initial phase of decline (group B).
The SIV-specific responses in three of the animals
(one of each clinical outcome) were compared at 2, 6,
and 12 weeks after inoculation. The responses generally
showed a decrease by 12 weeks after infection (Fig. 5).
SIV antigen-specific CD8 T cells were enumerated by
tetrameric binding in the Mamu A*-01 animal (RQI-5).
The CD8 population (1.05%) bound the MHC A*01-Gag
p11 complex; 0.95% of CD8 T cells produced IFN- at 1
year after infection (data not shown). RQI-5’s anti-Gag
responses appeared to be directed mainly toward the
HLA A*01 restricted epitope, as the percentage of CD8
T cells reacting was similar when peptide p11c or pep-
tide pool 1 (which includes p11c) were used as sources
of antigen, similar to what has been previously observed
by Kuroda et al. in 1998. The ELISPOT assays are likely
to be more useful than the tetrameric assays, as they can
elicit responses to many peptides and to all possible
haplotypes.
Thymic output in the SHIV-infected monkeys
We quantitated thymic output by TREC measurement
in the peripheral blood of three of the six SHIV-KB9-
infected rhesus macaques. The results are shown in Fig.
6. We observed that all monkeys had TREC levels of
40,000–100,000/106 PBMC before infection; these results
FIG. 3. Plasma viral RNA levels in rhesus monkeys infected with
SHIV-KB9. Plasma viral RNA levels were measured: (A) during primary
viremia, by 6 weeks after inoculation, and (B) at 10 weeks after
SHIV-KB9 inoculation. Infected monkeys were divided into three
groups: (A) those with profound CD4 T lymphocyte decreases and
failure to recover, (B) those with higher CD4 T lymphocyte counts and
partial recovery, and (C) those with high CD4 T lymphocyte counts that
did not demonstrate any signs of immunodeficiency. Each symbol
represents one animal. Limit of detection was 1000 copies/ml.
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are comparable with previously published findings for
juvenile monkeys (Sodora et al., 2000). After SHIV-KB9
inoculation we observed different patterns of TREC
change, consistent with the clinical outcomes described
above (Fig. 6): The monkeys with the low CD4 T cell
nadir and rapid disease progression displayed rapid
decreases (1 log) as early as 2 weeks postinoculation
that were either sustained (RBJ-5) or showed small fluc-
tuations with an overall downward trend (RAQ-5). In con-
trast, the animal without CD4 depletion showed persis-
tence in TREC levels throughout the course of the infec-
tion. A transient decline 2 weeks after inoculation was
followed by rapid return to preinoculation levels; this
could be due to a concurrent increase in CD8 CD45
RA cells. Even though both thymic cell generation and
peripheral cell turnover affect TREC levels, these results
confirm previous histological observations of marked
thymic disruption in SHIV-infected macaques (Li et al.,
1995) and suggest that thymic dysfunction is an impor-
tant determinant of disease progression in this SHIV
model.
DISCUSSION
The patterns of disease development and progression
after SHIV-KB9 intravenous inoculation of rhesus ma-
caques have been previously characterized (Reimann et
al., 1996, 1999). We observed yet another pattern that has
not been previously described after intravenous inocula-
tion of rhesus monkeys with SHIV KB9: two of six animals
in our cohort did not display any CD4 T cell depletion or
clinical signs of immunodeficiency, despite their having
been infected with the same viral stock and viral dose
and by the same route as the other animals.
This intriguing observation led to questions regarding
determinants of pathology and clinical outcome after
inoculation of different animals with the same patho-
genic clone. It might have been expected that the viral
clone would cause a more uniform pattern of clinical and
immunological decline. However this is not the case, as
we and others have observed. In vivo evolution of the
virus leading to loss of its pathogenicity very early in
infection versus host-immune or genetic factors offer
FIG. 4.Maturation of human gp120-specific antibody responses in monkeys infected with SHIV-KB9. Serial samples were obtained from the animals
at the indicated times after inoculation. The avidity of serum antibodies for HIV-1 envelope gp120 was determined by measuring the resistance of
serum antibody-envelope glycoprotein immune complexes to disruption by treatment with 2 M SCN in the ELISA assay. (A) Titer achieved in the
animals with the three different disease patterns; (B) Avidity index of the antibodies in the different animals. Group A: RBJ-5, RAQ-5; Group B: RHR-5,
RQI-5; Group C: RDO-5, RAP-5.
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alternative explanations for the differing course of each
individual animal.
Viral load has been shown to influence disease pro-
gression in humans infected with HIV (Mellors et al.,
1996), as well as in macaques infected with SIV or SHIV
(Chakrabarti et al., 1994; Reimann et al., 1996; Shibata et
al., 1997; Kozyrev et al., 2001). In fact, the highest levels
of SHIV-induced primary viremia were observed after
infection with 89.6P, the strain from which SHIV-KB9 was
cloned (Reimann et al., 1996); this virus has the highest
potential for causing acute and rapid CD4 T cell loss
compared to all previously developed chimeric strains.
These observations support the idea that virus replica-
tion does influence disease progression in these ani-
mals; however, it must not be the only parameter, since
in our animals very different clinical outcomes were
seen, despite comparable levels of virus load during
acute infection and similar kinetics of viral replication
during established infection. Indeed, in a recent study,
pathogenicity of SHIV-89.6P molecular clones did not
seem to correlate with initial viral replication (Kozyrev et
al., 2001). Dual-tropic viruses are not homogeneous in
their coreceptor usage, but comprise a continuum of
variants that use CXCR4 and CCR5 to different degrees.
It has been shown that coreceptor utilization plays a
critical role in viral pathogenesis, with differential target-
ing of lymphocyte populations during acute infection
(Harouse et al., 1999). It is possible that KB9 might have
FIG. 5. HIV and SIV-specific T lymphocyte responses (interferon- production). Peripheral blood mononuclear cells (PBMC) from the SHIV-infected
monkeys were stimulated with four different SIV Gag peptide pools, SIV Nef, and HIVgp120. IFN--secreting cell magnitudes are given as total
responses per individual, calculated as the sum of responses against the different antigens. The number of antigens recognized per individual is
indicated within the bars. RDO-5: Group C; RHR-5: Group B; RBJ-5: Group A.
FIG. 6. Change in TREC levels during SHIV-KB9 infection of rhesus macaques in the animals with low CD4 T cell counts and disease progression
(RBJ-5, RAQ-5), and in those without evidence of CD4 T cell decline or clinical immunodeficiency (RDO-5).
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shifted in its coreceptor usage, allowing for different
pathology in the animals. We attempted to detect such
differential evolution of the virus in the animals with the
distinct clinical outcomes; however, we found that all
animals had retained the original V3–V5, as well as GP41
and nef sequences in their predominant circulating virus
(data not shown). It is possible that critical sequence
changes might have occurred in other regions; such
studies are currently in progress in our laboratory. How-
ever such mutations would have had to occur very rap-
idly after infection, which might have been difficult with a
monoclonal virus. We therefore hypothesized that host
factors, whether genetic (chemokine receptors) or immu-
nologic, must be more important in determining initial
disease progression patterns.
An explanation for the rapid CD4 T cell decline in the
animals might be the ability of the virus to disrupt the
thymus (Li et al., 1995; Ilda et al., 2000). It has been
previously shown in histopathologic studies that the
SHIV 89.6P strain is found in the thymus very early after
inoculation, disrupting thymic architecture, and a large
number of apoptotic cells was observed in the thymus as
early as 14 days postinfection with SHIV 89.6P (Ilda et al.,
2000). We examined the thymic output in our cohort of
infected animals by TREC quantitation. Our data show
two distinct patterns of thymic output kinetics during the
course of infection: The animals in which the CD4 T
cells decline displayed a decrease of TREC as soon as
2 weeks after inoculation, whereas the animals with
preserved CD4 T cell counts sustained their preinfec-
tion levels of TREC. To our knowledge, this is the first
report of thymic output using TREC assays in retrovirus-
infected monkeys. It should be kept in mind that TREC
measurements are influenced not only by new thymic
lymphocyte generation, but also by peripheral T cell
proliferation; thus, cell conversion from naı¨ve to “activ-
ated” phenotype as a result of antigenic stimulation will
also decrease TREC levels and may be a contributing
factor to the pattern of TREC decline we observed in the
progressing animals. We further observed that there
were profound decreases of CD4CD45RA T lympho-
cytes as early as 2–4 weeks postinoculation in the pro-
gressing animals, but not in the nonprogressing ones;
however, CD8CD45RA T lymphocytes did not exhibit a
corresponding decrease casting doubt on the utility of
this marker as an index of thymic output (Champagne et
al., 2001).
We attempted to further define the immunologic re-
sponse to the SHIV-KB9 clone, by antibody development,
T cell cytokine secretion, and lymphocyte surface marker
expression in the animals with the different disease
patterns.
We used antibody responses to recombinant HIV-1MN
gp120 to study the nature of virus-specific antibody re-
sponses to SHIV infection. Our findings confirmed previ-
ous observations (Cole et al., 1998) of a lengthy matura-
tion of envelope-specific antibodies in rhesus macaques,
and of similar patterns of antibody maturation in pro-
gressing versus nonprogressing animals. The exception
to this was the two animals with the rapid, profound, and
sustained CD4 T cell decreases, which did not mount
an adequate antibody response, similar to what was
previously observed by Reiman et al. in 1999, Lu et al. in
1998, and Ilda et al. in 2000, using commercial HIV-1
ELISA, agglutination, or Western blot assays. Of interest
is the fact that animals from group B achieved higher
antibody titers than those of group C. We found that
antibody avidity did not reach maximum values (which
were of moderate degree—less than 50%), until 10
months postinoculation, whereas the antibody titer
achieved high levels much earlier (by 3–4 months in our
study), thus preceding antibody maturation by 6–7
months. The lack of correlation of antibody titer and
avidity with clinical outcome suggest that antibody pro-
duction is only one of several immune variables associ-
ated with protection. Interestingly, antibody responses to
tetanus toxoid were produced in high titer and avidity in
all animals; they were maintained in all but the animal
with the most profound immunodeficiency, suggesting
that the loss of antibody may be a direct consequence of
the marked CD4 T cell defect.
Cellular immune responses were studied by compar-
ing activation levels of different T cell subsets at various
stages postinoculation. An interesting pattern was ob-
served, according to which, the animals with a lack of
CD4 T cell depletion showed the least activation, as
measured by expression of HLA-DR and CD69 and lack
of expression of CD45 RA on CD8 T cells. The progress-
ing animals with the partial CD4 cell rebound displayed
much more pronounced CD8 T cell activation by all
markers. These increases parallel the increases in the
absolute number of CD8 T cells observed 5–15 weeks
after infection.
The above observations support previously reported
findings, that a “wave” of lymphocyte activation occurs
soon after primary SHIV infection (Wallace et al., 1999).
This activation may correlate with virus replication and
direct and indirect CD4 T cell killing or with antiviral
cytotoxic T lymphocyte responses. When studying spe-
cific cellular immune responses by ELISPOT, we ob-
served that the number of cells producing interferon-
was highest during the acute phase (2 weeks postinocu-
lation) in all animals tested and generally subsided by 12
weeks postinoculation. We observed that the animals
with CD4 T cell loss and partial rebound had higher
responses in the acute infection stage than those with
CD4 T cell decline. These data suggest that additional
factors, possibly related to differential viral entry within
different immune cell types, might be primarily respon-
sible for protection against disease in these latter ani-
mals.
In conclusion, SHIV-KB9 infection can be nonpatho-
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genic in the rhesus macaque; divergent clinical out-
comes seem to be related to several differences in host
response to the infection. Even though no differences
were observed in the viral load kinetics, differences in
immune activation and response patterns of CD8 and B
lymphocytes and in thymic output were observed in the
animals that progressed, as compared with those that
did not. Ongoing studies on the viral genotype and on
coreceptor utilization may shed further light on viral and
host determinants of nonpathogenic SHIV infection. Our
findings have implications for the use of this virus in
vaccine studies.
MATERIALS AND METHODS
Animals
The study group comprised six juvenile rhesus ma-
caques (Macacca mulatta), bred at the Yerkes Regional
Primate Center, Atlanta, GA (RDO-5, RAP-5, RAQ-5,
RHR-5, RBJ-5, RQI-5). The animals were housed and
maintained according to the guidelines of the Committee
for the Care and Maintenance of Primates of Emory
University and the “Guide for the Care and Use of Lab-
oratory Animals” (National Research Council, National
Academic Press, Washington, DC, 1996). Animals were
sedated with ketamine before venipuncture or vaccina-
tions and were examined clinically while under anesthe-
sia. All animals were inoculated intravenously with SHIV-
KB9 grown in CEMx174 cells. The animals had previously
been immunized with three doses, at 2-month intervals,
of tetanus toxoid (0.5 ml im). Tenofovir (PMPA) is a non-
nucleoside reverse transcriptase inhibitor that was used
as antiviral therapy in some animals, as its once daily
dosing (20 mg/kg) allows ease of administration (kindly
provided by N. Bischofberber, Gilead Sciences, Foster
City, CA).
Virus
The parental virus, SHIV 89.6P, has been previously
described as a pathogenic virus inducing rapid CD4
cell depletion and AIDS-like illness in rhesus monkeys
(Karlsson et al., 1997). Briefly, KB9 contains the tat, rev,
vpu, and env genes of HIV-1 in an SIVmac 239 (nef open)
background. The env gene is derived from a cytopathic,
primary HIV-1 isolate, 89.6, which is tropic in vitro for
both macrophages and T cells. The viral genome is
contained on two plasmids and virus is produced by
ligation of the SphI-digested 5 and 3 proviral halves,
followed by transfection of CEMx174 cells, as described
previously (Reimann et al., 1996). The infection of juvenile
rhesus monkeys (M. mulatta) with SHIV 89.6, and four
serial in vivo passages by intravenous blood inoculation,
led to the generation of a molecular clone, KB9, which,
after ligation to the SIVmac 239 5 proviral half, induced
rapid decreases of CD4 lymphocytes in all three mon-
keys initially inoculated (Reimann et al., 1996). The in-
creased virulence of this virus was attributed to differ-
ences in envelope ectodomain sequences, increasing
membrane fusogenicity (Etemad-Moghadam et al., 2000,
2001). This chimeric virus was obtained from Dr. K.
Reimann, Beth Israel Deaconess Medical Center, Bos-
ton, MA. The virus stock was propagated on rhesus
PBMC and the titer determined by titration in CEMx174
cells. Monkeys infected with this virus received 10–1000
animal infectious doses, as previously described (Karls-
son et al., 1997; Reimann et al., 2001).
Quantitation of plasma viral RNA
A QC-PCR method developed for SIVmac was used, as
previously described (Zhou et al., 1999). Primers used in
this assay hybridized with SIV Gag. Briefly, plasma RNA
was extracted and then reverse transcribed in the pres-
ence of 500 copies of competitor RNA. These reaction
products were amplified by PCR and separated on an
agarose gel. The viral RNA yielded a 336-bp band, and
the control yielded a 253-bp band. Viral RNA levels were
calculated from the dilution of a sample that produced a
visual signal equivalent to the internal control.
Staining and phenotypic analysis of lymphocyte
subsets and p11c-specific CD8 T cells
The monoclonal antibodies (mAbs) used for surface
staining included the following directly conjugated to
FITC, PE, or PerCP: CD3 (clone SP34, Pharmingen, San
Diego, CA), CD4, CD8, CD20, CD69, HLA-DR (Becton–
Dickinson, San Jose, CA), CD45RA (RD1-2H4); and PE-
coupled tetrameric Mamu-A*01/p11C. Immunophenotyp-
ing was done on lysates of freshly drawn whole blood.
Briefly, 100 l volumes of whole blood were aliquoted
into 12  75 mm polystyrene tubes and incubated with
directly conjugated surface-staining antibodies for 30
min at room temperature. Red blood cells were lysed
with 2 ml FACSLyse solution (BDIS, San Jose, CA) for 10
min at room temperature and washed twice with wash
medium (phosphate-buffered saline (PBS) containing 2%
fetal calf serum). Stained cells were fixed in 1% parafor-
maldehyde and kept overnight at 4°C prior to acquisition
and analysis on a FACScan (BDIS). Isotype controls were
used to set negative gates. Relative percentages and
absolute numbers of cells in each subset were calcu-
lated using CellQuest Software (BDIS) and absolute lym-
phocyte counts were obtained from an automated cell
counter Sysmex K1000 with a manual differential.
Measurement of viral envelope glycoprotein-specific
antibody by ELISA
Serum samples from SHIV-KB9-infected macaques
were analyzed for their reactivity to recombinant HIV
envelope glycoprotein gp120MN (National Institutes of
Health, Bethesda, MD). MN is a monocytotropic labora-
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tory HIV-1 strain. ELISA was performed in microtiter
plates coated overnight with recombinant gp120 at 0.5
g/ml PBS. After blocking the wells with 3% nonfat dry
milk in PBS (BLOTTO), diluted monkey serum was added
to each well and incubated for 2 h at 37°C. Following
washing with PBS-0.05% Tween 20, the wells were incu-
bated with mouse anti-human IgG (Sigma) coupled to
horseradish peroxidase, for 1 h at 37°C. The wells were
again washed and incubated with ortho-phenyl-diamine
(OPD) substrate, and the optical density (OD) was mea-
sured at 490 nm using an automated plate reader (Dy-
natech). All experiments were run in duplicate. Serial
twofold dilutions of a pool of reactive sera were run to
construct a standard curve and titers of individual sera
are reported as titers off the linear range of the curve.
Several different dilutions of sera were run to ensure that
the absorbance value was within this linear range.
Measurement of viral envelope glycoprotein-specific
antibody avidity
The avidity of ELISA antibody against gp120 was mea-
sured by titration of sera in the presence or absence of
2 M sodium thiocyanate (SCN). The avidity index of
serum antibodies against HIV gp120 was calculated by
measuring the resistance of the serum antibody-enve-
lope glycoprotein complexes in the ELISA assay to 2 M
SCN, as previously described (Cole et al., 1998). Briefly,
recombinant viral gp120 was coated onto microtiter
plates as described above for the ELISA. All test sera
were again diluted in BLOTTO to produce an OD at 490
nm of about 1.0 to 1.5 and were plated in two sets of
duplicate wells. Following the serum incubation, dupli-
cate wells were treated in parallel with either PBS alone
or a solution of 2 M SCN in PBS (15 min at room tem-
perature). Following washing with PBS–0.05% Tween 20,
the wells were incubated with peroxidase-conjugated
anti-human IgG and developed as described above in
the ELISA procedure. The avidity index was calculated
from the ratio of absorbance value obtained with SCN
treatment to that observed with PBS treatment multiplied
by 100%.
Measurement of antibodies and antibody avidity to
tetanus toxoid
A specific ELISA assay for tetanus antibodies has
been established in our laboratory. Tetanus toxoid was
purchased from Connaught Laboratories and used at a
dilution of 1:400 in carbonate buffer. Sera were diluted at
1:1000 and the assays were performed as described
above.
ELISPOT assays
Elispot assays were performed using a modification of
recently described techniques (Haslett et al., 2000; Lars-
son et al., 1999). Briefly, cryopreserved peripheral blood
mononuclear cells (PBMC) were incubated at 3  105
cells/well with the antigen of interest in RPMI-1640 cul-
ture medium supplemented with 10% fetal calf serum and
penicillin (10 IU/ml)–streptomycin (10 mg/ml) onto 96-
well plates (Millititer, Millipore, Bedford, MA). The plates
had been precoated overnight with anti-interferon-
monoclonal antibody (5 g/ml, Pharmingen) and blocked
with culture media containing 10% fetal calf serum. The
incubation proceeded for 24–36 h at 37°C in a 5% CO2
incubator. The antigens of interest included four SIV gag
p55 peptide pools encompassing the whole gag region
(kindly provided by Dr. Harriet Robinson, Yerkes Primate
Research Center, Atlanta, GA), recombinant SIV nef,
HIVMN gp120 (NIH AIDS Research Reagent Program), or
staphylococcal enterotoxin B (SEB, Toxin Technologies,
Sarasota, FL, 10 ng/ml). All cultures were performed in
duplicate. The plates were subsequently washed four
times with PBS–0.05% Tween-20 (Sigma, St. Louis, MI)
and a secondary biotin-labeled anti-interferon- mono-
clonal antibody was added for 2 h at 37°C (clone 7-B6-1,
1 g/ml, MabTech, Stockholm, Sweden). The wells were
washed and avidin-peroxidase complex was added (Vec-
tastain ABC kit, Vector Laboratories, Burlingame, CA) for
1 h at room temperature. After washing, substrate was
added (diaminobenzidine (DAB), Research Genetics,
Huntsville, AL) and then finally rinsed out with water.
Resulting brown spots were counted with an ELISPOT
plate reader (Immunospot Analyzer, CTL, OH), each spot
representing IFN- production by a single cell. Data
were expressed as the number of spot-forming cells
(SFC) per 105 input cells after subtraction of the back-
ground and of the responses observed to the respective
antigens at baseline (time of inoculation), to exclude
cross-reacting activity and antigen impurity.
Thymic output assays
Thymic output was measured by quantitation of T cell
receptor (TCR) rearrangement circles (TREC), produced
during TCR rearrangement in the developing thymocytes.
Signal–joint TREC primers for human developed by
Douek et al. (Douek et al., 1998; McFarland et al., 2000)
were employed to amplify the corresponding DNA se-
quences of the rhesus macaques. Based upon the rhe-
sus macaque sequences, we developed a real-time PCR
for the TREC assay in macaques using the TaqMan
system to quantitate TREC in peripheral blood lympho-
cytes. The design of TaqMan probes, combined with the
5 to 3 nuclease activity of AmpliTaq Gold polymerase,
allows direct detection of PCR product by the release of
a fluorescent reporter during the PCR on the ABI Prism
7700 Sequence Detector. The TaqMan probe consists of
an oligonucleotide with a 5 reporter dye and a down-
stream 3 quencher dye. Each of the reporters is
quenched by 6-carboxy-tetramethylrhodamine (TAMRA).
When the probe is intact, the proximity of the reporter dye
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to the quencher dye results in suppression of the re-
porter fluorescence. During PCR, forward and reverse
primers hybridize to a specific sequence of the target
DNA. The TaqMan probe hybridizes to a target sequence
within the PCR product. The AmpliTaq Gold enzyme
cleaves the TaqMan probe with its 5 to 3 nuclease
activity. The reporter dye and quencher dye are sepa-
rated upon cleavage, thus resulting in increased fluores-
cence of the reporter. This process occurs in every cycle
and does not interfere with the exponential accumulation
of the product. The separation of the reporter dye from
the quencher dye results in increase in fluorescence for
the reporter. The increase in fluorescence (kinetics) is
measured and is a direct consequence of target ampli-
fication during PCR. The designed primers employed for
the TREC assay were MTRF, MTRH, and fluorescent
FAM-labeled probe MTRP (attached). Every real-time
PCR was run in a 50-l reaction containing 10 buffer, 5
mM MgCl2, 0.25 mM of each dNTPs and 500 mM of each
primers and probe. After 2 min of incubation at 50°C, and
10 min at 95°C for denaturation, the samples were sub-
jected to 60 cycles of PCR, with each cycle consisting of
30 s at 95°C and 30 s at 60°C. All the samples, as well
as the control standard of known amount of DNA, were
run either in duplicate or in triplicate.
The control standard DNA was the amplified monkey
TREC sequence with primers by Douek et al. in 1998
cloned in pCRII vector. After miniprep isolation, the plas-
mid standard DNA was quantified by spectrophotometer
and the number of copies per microliter calculated. The
determination of TREC copy number in the samples was
done by comparison of the number of PCR cycles at
which fluorescence was detected to the number of PCR
cycles.
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